1.Nosocomial Outbreak of Carbapenem-Resistant Acinetobacter baumannii in Intensive Care Units and Successful Outbreak Control Program.
Won Suk CHOI ; Su Hyun KIM ; Eun Gyong JEON ; Myeung Hee SON ; Young Kyung YOON ; Jung Yeon KIM ; Mi Jeong KIM ; Jang Wook SOHN ; Min Ja KIM ; Dae Won PARK
Journal of Korean Medical Science 2010;25(7):999-1004
Acinetobacter baumannii has been increasingly reported as a significant causative organism of various nosocomial infections. Here we describe an outbreak of carbapenem-resistant A. baumannii (CRAB) in the ICUs of a Korean university hospital, along with a successful outbreak control program. From October 2007 through July 2008, CRAB was isolated from 57 ICU patients. Nineteen patients were diagnosed as being truly infected with CRAB, four of whom were presumed to have died due to CRAB infection, producing a case-fatality rate of 21.1%. In surveillance of the environment and the healthcare workers (HCWs), CRAB was isolated from 24 (17.9%) of 135 environmental samples and seven (10.9%) of 65 HCWs. The pulsed field gel electrophoresis patterns showed that the isolates from patients, HCWs, and the environment were genetically related. Control of the outbreak was achieved by enforcing contact precautions, reducing environmental contamination through massive cleaning, and use of a closed-suctioning system. By August 2008 there were no new cases of CRAB in the ICUs. This study shows that the extensive spread of CRAB can happen through HCWs and the environmental contamination, and that proper strategies including strict contact precautions, massive environmental decontamination, and a closed-suctioning system can be effective for controlling CRAB outbreaks.
*Acinetobacter Infections/drug therapy/epidemiology/prevention & control
;
Acinetobacter baumannii/isolation & purification/metabolism/*pathogenicity
;
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Bacterial Agents/*therapeutic use
;
Child
;
Child, Preschool
;
*Cross Infection/drug therapy/epidemiology/prevention & control
;
*Drug Resistance, Multiple, Bacterial
;
Hospitals, University
;
Humans
;
Infant
;
Infection Control/*methods
;
*Intensive Care Units
;
Korea/epidemiology
;
Male
;
Middle Aged
;
Young Adult
2.Antibiotic prophylaxis with intravenous ceftriaxone and fluoroquinolone reduces infectious complications after transrectal ultrasound-guided prostatic biopsy.
Chunwoo LEE ; Dalsan YOU ; In Gab JEONG ; Jun Hyuk HONG ; Myung Soo CHOO ; Hanjong AHN ; Tai Young AHN ; Choung Soo KIM
Korean Journal of Urology 2015;56(6):466-472
PURPOSE: To assess the rates of infectious complications before and after the change of prophylactic antibiotic regimens in prostate needle biopsy. MATERIALS AND METHODS: The records of 5,577 patients who underwent prostate needle biopsy at Asan Medical Center between August 2005 and July 2012 were retrospectively reviewed. Group 1 (n=1,743) included patients treated between 2005 and 2009 with fluoroquinolone for 3 days, group 2 (n=2,723) included those treated between 2009 and 2012 with ceftriaxone once before the biopsy and fluoroquinolone before biopsy and continue therapy for 3 days, and group 3 (n=1,111) received the same treatment for more than 7 days after the biopsy. Univariable and multivariable logistic regression models addressed risk factors associated with infectious complication after prostate needle biopsy. RESULTS: Infectious complication after prostate needle biopsy developed in 18 (group 1), seven (group 2), and two patients (group 3) (p=0.001). In group 1, seven patients with infectious complication had positive blood cultures and harbored fluoroquinolone-resistant Escherichia coli, four had ceftriaxone susceptible isolates, and three had extended spectrum beta-lactamase-positive E. coli. Two patients in group 1 required intensive care because of septic shock. In multivariable analysis, the patients with combination of fluoroquinolone and ceftriaxone had significantly lower infectious complication rate than the fluoroquinolon alone (p=0.003). CONCLUSIONS: Antibiotic prophylaxis with ceftriaxone and fluoroquinolone before prostate needle biopsy decreased the risk of potentially serious infectious complications.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Antibiotic Prophylaxis/*methods
;
Biopsy, Needle/adverse effects/methods
;
Ceftriaxone/*therapeutic use
;
Cross Infection/epidemiology/etiology/*prevention & control
;
Drug Evaluation/methods
;
Drug Resistance, Bacterial
;
Drug Therapy, Combination
;
Escherichia coli/drug effects
;
Escherichia coli Infections/epidemiology/prevention & control
;
Fluoroquinolones/*therapeutic use
;
Humans
;
Incidence
;
Male
;
Middle Aged
;
Prostatic Neoplasms/*pathology
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Ultrasonography, Interventional
;
Young Adult